George m Milne, a Director, acquired 20,000 Common Shares on a direct ownership basis at a price of US$13.104 on December 21st, 2020. This represents a $336,741 investment into the company's shares and an account share holdings change of 100.0%.
Aurinia Pharmaceuticals is in the Biotechnology & Medical Research Sub Industry Group under the Healthcare Sector.
Aurinia Pharmaceuticals Inc. is a late-stage clinical biopharmaceutical company. The Company is focused on developing and commercializing therapies to treat targeted patient populations that are impacted by serious diseases. It is developing voclosporin in multiple indications. Voclosporin is an investigational therapy. It is developing voclosporin for the treatment of lupus nephritis (LN) and other proteinuric diseases. It is also advancing voclosporin ophthalmic solution (VOS), a topical formulation, for the treatment of dry eye syndrome (DES). Voclosporin is a calcineurin inhibitor (CNI). By inhibiting calcineurin, voclosporin blocks IL-2 expression and T-cell mediated immune responses and stabilizes the podocyte in the kidney.
No Comments